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Abstract
Septic shock is a complication that affects thousands of patients leading to high mortality
rates and increased healthcare costs. One treatment in the attempt to decrease poor
outcomes is corticosteroids. A systematic review was conducted to evaluate the impact
of corticosteroids on mortality in adult patients with septic shock. Databases searched
were CINAHL, PubMed, OVID, and Cochrane Library. A literature review was
performed and pertinent data from each article was recorded in data collection tables. A
total of six articles were critically analyzed. The Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) checklist and flow diagram were used to guide this
systematic review. The Critical Appraisal Skills Programme (CASP) checklist assisted in
assessing the quality of the articles selected. Cross study analysis was performed via the
data collection tables developed by this author. This analysis revealed five of the six
trials did not detect a decrease in mortality using corticosteroids in adult patients with
septic shock; the sixth study did document a reduction in mortality rate. Four studies
were underpowered which may affect the generalizability of their outcomes. Two studies
were adequately powered with one demonstrating positive outcomes. Possible benefits
were seen in the secondary outcomes such as faster resolution of shock and decreased
vasopressor use. Advanced practice nurses are having an increased prominent role in
patient care within healthcare. This role provides an opportunity for high quality
evidence-based results to be applied to improve patient care. Results of this systematic
review provide information to guide decision making by the advanced practice nurse as
well as suggestions for further study.

Table of Contents

Background/Statement of the Problem ........................................................................... 1
Literature Review............................................................................................................ 3
Theoretical Framework ................................................................................................. 15
Method ......................................................................................................................... 17
Results .......................................................................................................................... 20
Summary and Conclusions ............................................................................................ 36
Recommendations and Implications for Advanced Nursing Practice ............................. 41
References .................................................................................................................... 45
Appendices ................................................................................................................... 49

1

The Impact of Corticosteroids on Mortality in Adult Patients with Septic Shock
Background/Statement of the Problem
In the United States (US), more than 1.5 million people develop sepsis each year,
with about 250,000 ultimately dying from the disease process (Center for Disease Control
[CDC)], 2017). In addition, sepsis is the most expensive condition in hospitals,
accounting for $20.3 billion in the US in 2011 (Pfuntner, Weir, & Steiner, 2013). Singer
et al. (2016) indicated that even with advanced medical technologies such as vaccines,
antibiotics, and acute care, sepsis is the leading cause of death from infection. Sepsis can
progress into its most severe form, septic shock, defined as a “dysregulation of the host
response to infection, with circulatory, cellular, and metabolic abnormalities” (Annane et
al., 2018, p. 809).
The typical treatment regimen of septic shock includes intravenous fluids,
antibiotics, and vasopressors. This regimen has remained largely unchanged over the last
several years. The Surviving Sepsis Campaign first introduced guidelines in 2004, with
the goal of decreasing mortality from sepsis by 25% in five years. Although the initial
goal was not met, there were improvements in mortality rates, with some hospitals
experiencing a 20% decrease in mortality (Melville, Ranjan, & Morgan, 2015). Since the
first set of guidelines, three revisions have been made as new research is published. In
addition to fluids, antibiotics, and vasopressors, the organization makes recommendations
on adjunctive treatment options such as albumin, immunoglobulins, blood products, and
corticosteroids (Rhodes et al., 2017).
Corticosteroids are typically used as adjunctive in the treatment of septic shock.
The theory behind administering corticosteroids is that patients experience adrenal
insufficiency when critically ill and therefore, will benefit from an exogenous source
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such as intravenous steroids (Gupta & Ba, 2008). Despite this theory, there have been
conflicting results involving their use in septic shock. Lv, Gu, Chen, Yu, and Zeng
(2017) affirmed that controversies on the association between corticosteroids and
mortality in patients with septic shock exist. Studies may exhibit considerable variability
in mortality due to the time frame between the onset of septic shock and the initiation of
corticosteroid therapy (Lv et al.). Furthermore, the Surviving Sepsis Campaign suggested
a daily dose of 200mg IV hydrocortisone if adequate fluid resuscitation and vasopressor
therapy are not able to restore hemodynamic stability, although it must be noted that this
is a weak recommendation with a low quality of evidence (Rhodes et al.). The Surviving
Sepsis Campaign stated the low quality of evidence stems from contradictory results from
prior studies, in which some have exhibited a reduction in mortality rates while others
have demonstrated no difference in mortality (Rhodes et al.).
Since the latest publication of the Surviving Sepsis Campaign in 2016, recent
studies, including randomized control trials, have been published that may provide new
evidence on the effects of corticosteroids on mortality in adult patients with septic shock.
Therefore, the purpose of this paper is to conduct a systematic review to examine whether
the use of corticosteroids in septic shock impacts overall mortality in adult patients.
A review of the literature will be presented in the next section.
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Literature Review
The databases searched include PubMed, CINAHL, and OVID. Articles from
2000 to 2018 were included in the search. The keywords used to find relevant literature
included corticosteroids, steroids, sepsis, septic shock, hypothalamic-pituitary-adrenal
axis, and mortality.
Sepsis
Sepsis is a very common diagnosis in hospitals, and if undertreated or mistreated,
can cause multi-organ failure and possibly death. Healthcare providers encounter sepsis
frequently and recognition of sepsis and initiating treatment in a timely manner are
necessary to provide the best chance for survival (László, Trásy, Molnár, & Fazakas,
2015). An understanding of the pathophysiology of sepsis should be achieved to better
treat this disease process.
Definition and Pathophysiology. The most recent definition of sepsis by the
Third International Consensus Definitions Task Force (Sepsis-3) is defined as a “lifethreatening organ dysfunction caused by a dysregulated host response to infection”
(Singer et al., 2016, p. 2). Sepsis begins when the body’s localized defenses can no
longer defend itself from an external insult. Normally, the human body experiences a
myriad of attacks on its immune system daily and can fight its way back to a normal state
even when its primary defenses have been penetrated. László et al. (2015) stated that
these processes are well regulated and maintain an even balance that keep the
inflammatory response localized. When an attack overwhelms the body’s localized
defenses, the body reacts with a systemic inflammatory response to fight the infection.
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This dysregulated and unbalanced response affects the entire body and starts impairing
the function of vital organs (László et al.).
Sepsis may develop from an infectious or non-infectious process. The infectious
process could be caused by a bacterial, viral, or fungal source, whereas the non-infectious
process can occur from the inflammatory response of ischemia or muscle damage caused
by severe trauma, surgery, myocardial infarction, burns, or acute pancreatitis (Steen,
2009).
Diagnosis. Unlike many other diseases and conditions, there is no single
diagnostic test to diagnose sepsis. Sepsis requires the recognition of several factors to be
properly diagnosed. In intensive care units, the Task Force, assembled by the European
Society of Intensive Care Medicine and the Society of Critical Care Medicine,
recommended using the Sequential Organ Failure Assessment (SOFA) instrument to
identify patients with organ dysfunction (Singer et al., 2016). The Sequential Organ
Failure Assessment measures mortality risk although it can be used to clinically
characterize a septic patient (Singer et al.). This instrument examines assessment data
such as creatine, bilirubin, platelet levels, Pa02 and Fi02 ratios, mean arterial pressure
(MAP), and the Glasgow Coma Scale with a score ≥2 indicating organ dysfunction. A
new measure, called the quick SOFA (qSOFA) uses assessment data of mentation,
systolic blood pressure, and respiratory rate and is a simpler instrument to identify
patients with suspected infection who are likely to have poor outcomes (Singer et al.). A
positive qSOFA is an indicator for healthcare providers to investigate for organ
dysfunction, begin therapy, and consider a higher level of care with more frequent
monitoring (Singer et al.).
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Shock
The first classification system of shock was devised by the surgeon Alfred
Blalock in 1934 in which he categorized shock into four types: hypovolemic, cardiogenic,
neurogenic, and vasogenic (septic shock). As research evolved, a new classification
system, based on cardiovascular characteristics, was created by Hinshaw and Cox in 1972
that deemed septic shock as a form of distributive shock (Funk, Parrillo, & Kumar, 2018).
Shock is defined as “a life-threatening condition categorized by inadequate
delivery of oxygen and nutrients to vital organs relative to their metabolic demand”
(Strehlow, 2010, p. 57). The body is in a state in which there is insufficient energy to
keep up with its requirements to function properly. There are different types of shock,
which include hypovolemic, cardiogenic, anaphylactic, neurogenic, and septic shock.
Many of these types of shock are characterized by common symptoms. The early signs
typically include tachypnea, tachycardia, weak or bounding peripheral pulses, delayed
capillary refill, pale or cool skin, oliguria, and lactic acidosis (Stehlow). Late signs of
shock consist of central cyanosis, decreased mental status, weak or absent central pulses,
hypotension, and bradycardia (Stehlow). Each type of shock has other, more defining
signs and symptoms that may help clinicians identify and treat the type of shock
appropriately.
Septic Shock
Septic shock is the most severe form of sepsis. Singer et al. (2016) defined septic
shock as “a subset of sepsis in which underlying circulatory and cellular metabolism
abnormalities are profound enough to substantially increase mortality” (p. 9). The
clinical criteria used to identify septic shock are: (1) sepsis; (2) vasopressor therapy
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needed to elevate MAP ≥65 mmHg; and (3) lactate >2mmol/L (18mg/dL) despite
adequate fluid resuscitation (Singer et al.). The key variables in septic shock are the need
for vasopressors and fluid resuscitation to maintain an adequate blood pressure and
maintain lactate levels less than 2mmol/L. Failure to recognize septic shock and treat it
effectively can cause organ damage and death (Singer et al.).
Effects of Sepsis on the Hypothalamic-Pituitary-Adrenal Axis
The human body has defense mechanisms that protect itself from threats
occurring both inside and outside the body. The hypothalamic-pituitary-adrenal axis
(HPA) is comprised of the hypothalamus, pituitary gland, and adrenal glands. These
organs interact with each other to create a system that regulates many bodily functions
such as digestion, the immune system, mood and emotions. Although all these are
important functions, the most essential purpose of the HPA axis may be in controlling the
body’s reaction to stress (Schroeder et al., 2001).
When a stressful event occurs, the HPA axis is activated to respond and protect
the body from its potential harmful effects. A cascade of actions occurs in this stress
response. Corticotrophin-releasing hormone (CRH) is released from the hypothalamus
and acts on the anterior pituitary to release adrenocorticotrophic hormone (ACTH), which
stimulates cortisol production and release from the adrenal glands (Gupta & Bhatia,
2008). Cortisol is the hormone that is important in fighting stressful events such as
sepsis. The adrenal glands are incapable of generating enough cortisol in inflammatory
states caused by serious diseases (Williams, 2018). This impairment in HPA axis cortisol
production in the setting of sepsis may contribute to the body’s difficulty in returning to a
homeostatic state.
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In a study by Schroeder et al. (2001), the functional integrity of the HPA axis in
patients with severe sepsis was investigated by simulating the axis through a CRH test.
The pituitary-adrenal response was examined after the administration of CRH within 24
hours after diagnosis of severe sepsis and before discharge when patients were without
signs of sepsis. The CRH test involved injecting 100 µg of human CRH intravenously,
once between 8:00am and 9:00am. Plasma ACTH and cortisol levels were drawn 15
minutes before the administration of CRH, at the time of administration, then 15, 30, 45,
and 60 minutes after administration. Results demonstrated impaired plasma cortisol
response to a CRH test as well as lower plasma cortisol concentrations in non-survivors
compared with survivors of severe sepsis. Schroeder et al. concluded that dysfunction of
the endocrine system in severe sepsis may be evident through the reduced response to
CRH stimulation in this sample of patients. The deficiency in the HPA axis caused by
sepsis may contribute to mortality in this population.
Corticosteroids
Corticosteroids are a class of hormones that play an integral part in the body’s
daily functions. Corticosteroids have the ability to treat allergic and inflammatory
disorders and suppress unwanted immune system actions (Williams, 2018). There are
two types of corticosteroids, glucocorticoids and mineralocorticoids. Mineralocorticoids
refer to hormones, such as aldosterone, and are involved in regulating electrolyte and
water balance in the kidney. In the clinical setting, the term corticosteroid refers to
agents with glucocorticoid activity (Williams). This class contains the endogenous
cortisol, which as described prior, have immunosuppressive and anti-inflammatory
effects. Among others, different types of corticosteroids are used to mimic cortisol
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including hydrocortisone, dexamethasone, and prednisolone. Each have their own unique
onset, peak and duration of action although they all are intended to mimic cortisol’s
properties of suppressing or preventing undesirable allergic reactions or inflammation
(Williams).
Corticosteroids affect several stages in the inflammatory pathway by diffusing
across cell membranes and binding to glucocorticoid receptors causing changes in the
receptor (Williams, 2018). These changes include decreasing the production of T
lymphocytes, decreasing activity of natural killer cells, reversing macrophage activity,
and suppressing synthesis, secretion, and action of chemical mediators in the
inflammatory and immune response. These chemical mediators include interleukins,
prostaglandins, leukotrienes, bradykinin, serotonin, and histamine. Other mechanisms
inhibited are those involved in the production of cyclooxygenase-2, nitric oxide synthase,
and pro-inflammatory cytokines like tumor necrosis factor alpha and various interleukins
(Williams).
Corticosteroids are utilized in many areas of medicine. One such use is in the
management of asthma. Inhaled corticosteroids (ICS) are the most effective therapy in
maintaining asthma control through its anti-inflammatory effects on the airway
(Williams, 2018). Corticosteroid use has been shown to decrease mortality in this
population (Raissy, Kelly, Harkins, & Szefler, 2013). Corticosteroids are also used in the
management of irritable bowel syndrome (IBS). The role of corticosteroids in IBS is to
rapidly control symptoms and the acute phase of the disease with their anti-inflammatory
and immunosuppressive properties (Hall, 2011).
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The utilization of corticosteroids in conditions that effect different systems of the
body creates the possibility of a beneficial use in septic shock. Williams (2018) stressed
the acute use of corticosteroids should not be delayed in life-threatening conditions.
Success in reducing mortality in the management of asthma exacerbations possibly
supports the potential of corticosteroids in effecting mortality rates in septic shock.
Septic Shock Treatment and Management Strategies
Septic shock, a form of distributive shock, is defined as being “caused by a loss of
vasomotor control resulting in arteriolar and venular dilation, and after resuscitation with
fluids, characterized by increased cardiac output and decreased systemic capsular
resistance” (Funk et al., 2018, p. 96). The cardiovascular component, along with the
presence of an infection, forms the basis of treatment and management of septic shock.
The treatment of septic shock has remained largely unchanged over the last few
years despite the latest research and improvements in medicine. Singer et al. (2016)
asserted that even with advanced medical technologies such as vaccines, antibiotics, and
acute care, sepsis leads as the primary cause of death from infection. The typical
treatment regimen for septic shock has included antibiotics, fluid resuscitation, and
vasopressors.
The most current guidelines in managing septic shock by the Surviving Sepsis
Campaign include a long list of recommendations that may be used throughout the course
of septic shock. The initial guidelines in managing septic shock include:
1. Application of fluid challenge technique and continued fluid administrations as
long as hemodynamic factors continue to improve. Crystalloids are the preferred
fluid or initial resuscitation and subsequent fluid replacement.
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2. Administration of IV antimicrobials initiated as soon as possible after
recognition and within one hour for both sepsis and septic shock.
3. Norepinephrine is the first vasopressor recommended followed by vasopressin
and epinephrine. In some cases, dopamine and dobutamine may be used (Rhodes
et al., 2017).
Fluid Resuscitation. Fluid resuscitation is the first-line therapy in patients who
are experiencing septic shock. Hypotension and increased serum lactate levels are signs
of tissue hypoperfusion and are indicators for the initiation of fluid therapy. At least 30
ml/kg of IV crystalloid fluid should be given within the first three hours and additional
fluids given thereafter to maintain hemodynamic status (Rhodes et al., 2017). Providing
this therapy aids in decreasing the chances of organ dysfunction that could lead to further
deterioration in patients.
Antibiotics. The initial management strategies are key to survival when a patient
is presumed to be experiencing septic shock. The suspected infection needs to be
addressed by obtaining cultures from body fluids (blood, urine, peritoneal, and other
sources), beginning broad-spectrum antibiotics, and initiating infectious source control.
Identifying the source of infection is crucial as without this action treatment would not be
effective. Removing the source of infection may consist of removing a device such as a
peripherally inserted central catheter (PICC), draining an infected fluid such as an
abscess, or debriding infected tissue as seen in necrotizing pancreatitis. The broadspectrum intravenous antibiotics will provide the necessary treatment against the most
likely pathogens until exactly identified from obtained cultures (Seymour & Rosengart,
2015).
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Vasopressors. In conjunction with fluid therapy, vasopressors provide additional
assistance in maintaining adequate tissue perfusion. Vasopressors are initiated when
fluid therapy alone is not enough in providing hemodynamic stability. There are different
types of vasopressors that have an effect on different parts of the cardiovascular system,
with the intended action of raising blood pressure to an adequate level. Norepinephrine
has been the typical vasopressor of choice and recommended by various guidelines and
expert opinions (Seymour & Rosengart, 2015). In addition, vasopressin at a fixed rate
(0.03-0.04 U/min) in patients with increased norepinephrine requirement is suggested as
a supplementary medication therapy (Seymour & Rosengart). These medications, along
with fluid resuscitation, are important in the treatment and management of septic shock.
Adjunctive Treatments. There are multiple adjunctive therapies that can be used
to treat septic shock. In fluid therapy, colloids such as albumin have been used to assist
with blood pressure control. Hydroxyethyl starch, another colloid, had previously been
used as well, although this has been shown to increase rates of renal replacement therapy
(Seymour & Rosengart, 2015). Recently, vitamin C has been researched in treating
sepsis and septic shock. The anti-oxidant and enzyme cofactor properties of vitamin C is
thought to reverse sepsis induced organ dysfunction (Marik, 2018); however, the use of
vitamin C requires more research to be considered part of the septic shock treatment
regimen. A more widely used adjuvant is corticosteroids. The rationale for their use is
patients experience adrenal insufficiency during sepsis and would benefit from an
exogenous source such as intravenous steroids.
Use of Corticosteroids in Septic Shock
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Corticosteroids have been used in different areas of medicine for many years.
Their use in sepsis and septic shock was started soon after an observation by Sir William
Osler, in the 1900s, who postulated that many suffering from a severe infection were
more inclined to die from the body’s inflammatory response to the infection rather than
the infection itself (Salluh & Póvoa, 2017). This observation, coupled with the fact that a
patient’s HPA axis is suppressed when critically ill, led medical professionals to utilize
corticosteroids in septic patients. Salluh and Póvoa (2017) believe the ability to manage
the inflammatory response caused by an infection would clinically stabilize patients and
increase survival rates.
Many types of studies ranging from as far back to the 1980s were used to support
the recommendations made by the Surviving Sepsis Campaign. It is important to note
that in the 1980s steroids were used more often instead of adequate fluid therapy, early
initiation of antibiotics, early collection of blood cultures, and lactate monitoring (Salluh
& Póvoa, 2017). The use of corticosteroids in septic patients became standard after the
Surviving Sepsis Campaign released the first guidelines in 2004 (Salluh & Póvoa). The
organization’s latest guidelines note that the recommendation related to corticosteroids is
weak with a low quality of evidence. Their efficacy in reducing mortality in this specific
population has been debated. The Surviving Sepsis Campaign stated their designation of
low quality of evidence comes from contradictory results from prior studies with some
exhibiting a reduction of mortality rate while others show no difference in mortality
(Rhodes et al., 2017). Lv et al. (2017) supported this and noted controversies on the
association between corticosteroids and mortality in patients with septic shock exist. The
authors mention the possibility of substantial variability in mortality due to the time
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frame between the start of septic shock and the initiation of corticosteroid therapy (Lv et
al.).
In a prospective observational study conducted by Ferrer et al. (2009), researchers
analyzed the effectiveness of four treatments including early broad-spectrum antibiotics,
fluid challenge, low-dose steroids, and drotrecogin alfa. This later drug, drotrecogin alfa,
was a recombinant form of human activated protein C that exhibited anti-inflammatory
effects but has since been withdrawn from the market due to its failure to demonstrate
survival benefit. Two thousand seven hundred ninety-six adult patients from 77 intensive
care units were observed and the primary outcome measured was mortality. Ferrer et
al.’s findings indicated there was no association between the administration of low-dose
steroids in septic shock and mortality. The effectiveness of each treatment was measured
using propensity scores: early-broad spectrum antibiotics (odds ratio, 0.67; 95%
confidence interval (CI), 0.50-0.90, P = 0.008), drotrecogin alfa (odds ratio, 0.59; 95%
CI, 0.41-0.84, P = 0.004), fluid challenge (odds ratio, 1.01; 95% CI, 0.73-1.39, P =
0.966), and low-dose steroids (odds ratio, 1.04; 95% CI, 0.85-1.28, P = 0.688). No risk
or benefit was found with use of low-dose steroids, but it is important to note that the
observational design may have limited the results of the study. The authors revealed the
possibility of the results being influenced by different patient presentations among the
intensive care units examined and current trends in septic shock management (Ferrer et
al.).
Duane et al. (2014) evaluated the benefit of early low-dose corticosteroid in
patients with septic shock. The study included 6,663 patients of whom 1,838 were
administered a low-dose corticosteroid intravenously within 48 hours of being diagnosed
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with septic shock and were compared to patients who did not receive low-dose
corticosteroids. The primary outcome of 30-day mortality was assessed. Results showed
the group that received the corticosteroid therapy was associated with a similar 30-day
mortality when compared with the group who did not receive corticosteroid therapy
(35.5% vs 34.9%). Duane et al. determined early-administration of corticosteroids does
not decrease mortality in septic shock patients.
Recent studies, including randomized control trials, have been published since the
latest recommendations that may provide new evidence on the effects of corticosteroids
on mortality in adult patients with septic shock. In addition, the standard of care should
have been modified since the release of the Surviving Sepsis Campaign’s initial
guidelines in 2004. Randomized control trials published after this date may offer
different evidence than those conducted before release of the guidelines. These
randomized control trials will be included in the systematic review.
Next, the framework that will be used to guide this research will be presented.
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Theoretical Framework
The theoretical framework utilized to guide this systematic review will be the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The
aim of PRISMA is to assist authors in generating a clear and comprehensive reporting of
systematic reviews and meta-analyses. Systematic reviews and meta-analyses are
important research in healthcare as they are high level quality studies and can assist
clinicians in creating evidence based clinical practice guidelines (Moher, Liberati,
Tetzlaff, Altman, & The PRISMA Group, 2009). The focus of PRISMA is on
randomized control trials, but it can also be used in reporting systematic reviews of other
types of research. PRISMA consists of a 27-item checklist (Appendix A) and a fourphase flow diagram (Appendix B).
The PRISMA checklist pertains to the content of a systematic review and assists
the researcher in structuring the report in an organized manner. It summarizes results
from multiple studies into a single succinct document. The checklist contains seven
major headings such as title, abstract, introduction, methods, results, funding and lastly
includes several sub-headings (Moher et al., 2009).
The four-phase flow diagram depicts the course of studies through the different
stages of the systematic review process. It guides the researcher in the identification and
selection of studies. The diagram’s four phases are identification, screening, eligibility,
and inclusion (Moher et al., 2009). Identification involves discovering studies or records
within databases and other sources. Through use of the databases, the researcher
combines search terms in different combinations and applies limits such as a specific
population, years of search, and English language only. This results in a specific number

16

of studies. The screening phase is comprised of eliminating duplicate studies, including
screening the articles for ones that are pertinent to the research question. The eligibility
phase entails omitting studies that may not meet specific inclusion and exclusion criteria.
Finally, the inclusion phase is the final number of studies that will be used in the
systematic review.
To assess the quality of articles selected, the Critical Appraisal Skills Programme,
(CASP) will be used. The Critical Appraisal Skills Programme enables the researcher to
systematically assess the trustworthiness, relevance, and results of studies (CASP, 2018).
This program contains eight critical appraisal tools that can be used in systematic
reviews, randomized control trials, cohort studies, and others. The checklist used in this
research project was the CASP Randomized Control Trial Checklist (Appendix F). This
checklist is comprised of 11 questions divided into three sections. The sections cover
broad issues such as what the results are, whether they are valid, and if the results will
help locally (CASP). Through utilization of this checklist randomized control trials can
be successfully appraised to create a valid systematic review.
Next, the methods that will be used to guide the research will be discussed.
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Method
Purpose
The purpose of this systematic review was to examine whether the use of
corticosteroids, in septic shock, impacts overall mortality in adult patients. Outcomes
examined included corticosteroid administration compared to no corticosteroid
administration in the management of septic shock on mortality rates. The research
question examined was: Does the administration of corticosteroids in septic shock
decrease mortality in adult patients?
Inclusion/Exclusion Criteria
Inclusion criteria included randomized control trails published from 2008 to 2018.
Studies must have included participants 18 years of age or older and experiencing septic
shock. Studies must have been peer reviewed and written in the English language.
Lastly, studies must have compared the administration of corticosteroids to no
corticosteroids for the treatment of septic shock and impact on mortality rates. Exclusion
criteria were articles published prior to 2008, participants less than 18 years old, nonEnglish language articles, and articles that were not randomized control trials.
Search Strategy
A comprehensive search was conducted using the CINAHL, PubMed, OVID, and
Cochrane Library databases. Keywords used included sepsis, septic shock,
corticosteroids, steroids, and mortality.
Using the PRISMA four-phase diagram, studies were identified, screened for
duplicates, and assessed for eligibility, which resulted in a select number of studies to be
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used in the systematic review. This provided transparency and ensured a careful
selection of studies necessary to conduct the systematic review (Moher et al., 2009).
Data Collection
Two data collection tables, created by the author of this paper, was used to collect
and organize information extracted from the selected studies. Data collected in Table 1
included the studies’ purpose, design, sample, mortality endpoint, and corticosteroid used
and dose. Table 2 included any identified placebo (no corticosteroid), mortality rate, key
findings, and limitations. Organizing data into these tables ensured a clear means of
assessing and examining significant information from each study.
Table 1.
Data Collection Tool 1
Study:
Purpose

Study Design

Sample

Mortality Endpoint

Corticosteroid

Demographics

Table 2.
Data Collection Tool 2
Study:
Identified Placebo

Mortality Rate
Corticosteroid

Key Findings
Placebo
(No corticosteroid)

Limitations
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Critical Appraisal
The quality of the studies was assessed using the Critical Appraisal Skills
Programme (CASP) Randomized Control Trial Checklist. As described in the theoretical
framework section, this 11-question tool validates the results of each trial, assesses the
preciseness of treatment results, and considers clinically important outcomes (CASP,
2018). This checklist guarantees the selected studies are of the highest quality. Each
study was appraised and their results reported.
Cross Analysis
Once the studies have been critically appraised, a cross-study analysis was
conducted. The information was recorded in a table created by the author to evaluate the
similarities and differences regarding the impact of corticosteroids on mortality in
patients’ experiencing septic shock (Table 3).
Table 3.
Cross Analysis
Author,

Mortality Rate

Resolution of

Vasopressor

Year

at Day 28

Shock

Usage

Next, the results of the systematic review will be discussed.

Length of Stay (LOS)
ICU

Hospital
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Results
The PRISMA flowchart (Appendix B) and the inclusion/exclusion criteria were
used to select articles that were applicable for this systematic review. The breakdown of
the search strategy is depicted in Appendix C. The original search terms ceded 237
results. After eliminating duplicate articles, there were 165 remaining for review. The
titles and abstracts were evaluated to determine appropriateness looking specifically for
inclusion and exclusion criteria. This yielded 18 articles. The full-text of these articles
were read and again, inclusion and exclusion criteria used, to decide if they could be
applied for this review. A total of six articles remained and were used in this systematic
review. Key information was extracted and inputted onto the data collection tables in
Appendices D and E. After analyzing the obtained articles’ data, each study was
summarized as shown in the following section. The studies are presented in
chronological order. In addition, the studies were critically appraised using the CASP
checklist (Appendix F).
The randomized control trial conducted by Sprung et al. (2008) (Appendices D1
& E1) evaluated the efficacy and safety of low-dose hydrocortisone in patients with
septic shock. Patients were enrolled from March 2002 to November 2005 at 52 ICUs in
nine countries. Enrollees needed to be 18 years or older, have clinical evidence of
infection and a systemic response to the infection, an onset of shock within the previous
72 hours, and hypoperfusion or organ dysfunction related to sepsis. Excluded were those
who had an underlying disease with a poor prognosis, a life expectancy of less than 24
hours, immunosuppression, and treatment with long-term corticosteroids within the past
six months or short-term corticosteroids within the last four weeks. Of the 500 patients
enrolled, one withdrew consent. The rest were divided into two groups: the
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hydrocortisone group and placebo group. The 251 participants in the hydrocortisone
group had a mean age of 63 + 14 years with a mean SOFA score of 10.6 + 3.4. The
group was 66% male. The 248 participants in the placebo group had a mean ago of 63 +
15 with a mean SOFA score of 10.6 + 3.2 consisting of 67% male gender. The study’s
main endpoint was death at 28 days in patients who did not have a response to
corticotropin. Other endpoints were death at 28 days in patients with a corticotropin
response, mortality rate in the hospital, ICU, and overall. Also, the rate of shock reversal,
and length of stay (LOS) in the ICU and hospital were assessed. The study drug,
hydrocortisone, was given intravenously as a 50 mg bolus every 6 hours for 5 days, then
every 12 hours for days 6 to 8, every 24 hours for days 9 to 11, and then stopped. Vials
containing placebo were given in the same manner.
The study revealed (Appendix E1) there was no significant difference between the
two groups in the rate of death at 28 days among overall patients and those with and
without a response to corticotropin (P=0.51). Overall, 34.3% of the hydrocortisone group
died while 31.5% of the placebo group died. In those with no corticotropic response,
39.2% of the hydrocortisone group and 36.1% of the placebo group died whereas 28.8%
of the hydrocortisone group and 28.7% of the placebo group died in those with a
corticotropin response. The hospital and ICU discharge 28-day mortality were similar in
both groups. The reversal of shock was similar among both groups as well. In terms of
median time until reversal of shock, the hydrocortisone group experienced a shorter time
of 3.3 days while the placebo group required 5.28 days. The LOS was similar in both
groups for both in hospital and in ICU. Lastly, the hydrocortisone group experienced

22

more adverse events such as an increased rate of superinfections, hyperglycemia, and
hypernatremia.
Critical analysis of the Sprung et al. (2008) study using the CASP checklist
(Appendix F1) revealed a less precise treatment effect due to a sample size of 500 instead
of the 800 patients needed the achieve a statistical power of 80%. Also, one patient was
not accounted for at the end of the trial due to withdrawal of consent after randomization.
Some patients did openly receive corticosteroids after enrollment due to allergic
reactions, laryngeal edema, bronchospasm, brain edema, replacement of long-term
corticosteroid therapy whose history was unknown at enrollment, acute respiratory
distress syndrome, and septic shock. This rate was similar among the hydrocortisone and
placebo group at 4.4% and 4.0%, respectively.
The study conducted by Arabi et al. (2010) (Appendices D2 & E2) examined the
effect of low-dose hydrocortisone in patients with cirrhosis who presented with septic
shock. The study was a randomized double-blind placebo-controlled trial conducted at a
900-bed tertiary care academic hospital on a 21-bed medical-surgical ICU. Patients
enrolled required to be aged 18 years or older with liver cirrhosis who presented with
septic shock within 72 hours of the onset of hypotension. Patients were excluded if there
was evidence of hemorrhagic shock, known adrenal insufficiency, any prior systemic
steroid usage, contraindications for systemic steroids, post-cardiac arrest, and do-notresuscitate status. Of the 140 patients that were screened, 75 were enrolled and randomly
allocated into two groups. The hydrocortisone group was 44% female with a mean age of
60.6 + 12.6 and mean SOFA score of 14.6 + 3.7. The placebo group was also 44%
female with a mean age of 59.3 + 12.2 and mean SOFA score of 14.3 + 3.7. The primary
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endpoint of this study was 28-day all-cause mortality and secondary outcomes included
ICU and hospital mortality at 28 days, shock reversal, and vasopressor-free days.
Patients received intravenous bolus injections every six hours of either 5mL of 50 mg of
hydrocortisone or placebo. This was given until shock resolved which was defined as a
stable blood pressure (MAP>65) without a vasopressor for 24 hours. At this point, the
dose was reduced by 1 mL every 2 days until discontinued.
Results of this study (Appendix E2) demonstrated no significant difference
between the hydrocortisone and placebo groups in 28-day mortality (P=0.19). Deaths in
the hydrocortisone group accounted for 85% of the patients while the placebo group
encountered 72% deaths. The ICU (P=0.86) and hospital LOS (P=0.90) were similar in
both groups. Mortality was also similar in both groups in the ICU and hospital (P=0.64
and P=0.82, respectively). ICU mortality was 62% and 67% in the hydrocortisone and
placebo group, respectively. Hospital mortality was 87% in those receiving
hydrocortisone and 89% in those receiving placebo. The hydrocortisone group did show
some improvement in hemodynamic parameters. There were more patients in the
hydrocortisone group who experienced shock reversal (62%, P=0.05) and more
vasopressor-fee days (6.8 days, P=0.54) than the placebo group (39% and 5.6 days).
When looking at adverse events, severe hyperglycemia and gastrointestinal bleeding was
more prevalent in patients receiving hydrocortisone. There existed some limitations in
this study such as the single center setting that could affect generalizability. Others
included the long length of randomization of 72 hours and the use of etomidate in some
patients that has been proven to cause adrenal suppression.
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Upon critical appraisal of the Arabi et al. (2010) study (Appendix F2), the CASP
checklist revealed that the groups were not treated equally. There were five patients in
the placebo group that ended up receiving corticosteroid therapy due to life-threatening
hypotension. Because of this, they were moved to the other study arm and considered
crossovers. Also, blinding was opened for one patient at the primary physician’s request,
but the therapy was continued as planned. Despite these factors, the trial did clearly
address the focused issue, groups were similar at the start of the trial, and all the patients
were accounted for at the trial’s conclusion. Although 150 patients were required,
allocation of patients was stopped at 75 after a planned interim analysis revealed it was
unlikely that a treatment benefit would be evident if it were completed to the targeted
sample size.
In the study by Gordon et al. (2014) (Appendices D3 & E3), researchers tested for
an interaction between vasopressin and corticosteroids in septic shock. The study was a
prospective open-labeled randomized controlled trial conducted between October 2009
and March 2012 at four adult ICUs in London teaching hospitals. Inclusion criteria
consisted of adult patients greater than 16 years old who had sepsis requiring
vasopressors despite intravenous fluid administration. There were many exclusion
criteria as described in the appendix that included patients who received a previous
continuous infusion of vasopressors during the current hospitalization, had an ongoing
requirement for systemic steroids, death anticipated within 24 hours, or enrollment in
another trial that may interact with study drugs. Sixty-one patients were assigned to one
of two groups: hydrocortisone or placebo. All patients received vasopressin and either
hydrocortisone or placebo once the vasopressin was titrated to 0.06 U/min. The
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hydrocortisone group comprised of 58% males with a mean age of 61 and APACHE II
score of 19 while the placebo group was 60% male with a mean age of 60 and APACHE
II score of 20. The primary outcome of this study was the difference in plasma
vasopressin concentration between the two groups. Secondary outcomes included
difference in vasopressin requirements and 28-day, ICU, and hospital mortality.
Hydrocortisone was given as a 50 mg IV bolus every 6 hours for 5 days, every 12 hours
for 3 days, and then once daily for 3 days. The placebo (0.9% saline) was given in the
same way as the study drug.
The primary outcome of plasma vasopressin levels was found to be no different
between the two groups (64 pmol/L difference at 6 to 12-hour time point, 95% CI, -32 to
160 pmol/L) (Appendix E3). There was also no difference in mortality rates. The 28-day
mortality was 23% in the hydrocortisone group and 23% in the placebo group (-0.01;
-0.22, 0.20). ICU mortality in the hydrocortisone group was also 23% while 27% of the
placebo group died (-0.04; -0.26, 0.18). Hospital mortality was 26% in the
hydrocortisone group and 30% in the placebo group (-0.04; -0.27, 0.18). The value in
parentheses is the difference in proportions (vasopressin and hydrocortisone minus
vasopressin and placebo) and 95% CI. In terms of vasopressin requirements, the
hydrocortisone group was weaned off of the vasopressor more quickly, having a 3.1 days
shorter duration and halving the total dose requirement than the placebo group (P=0.001).
Limitations to this study included the small number of participants which has limited
power to detect differences in clinical outcomes. The trial was powered to detect a
difference in plasma vasopressin levels after reaching a maximum rate of vasopressin and
corticosteroid administration. Some patients received norepinephrine first as suggested
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by the Surviving Sepsis Campaign guidelines. These patients were weaned off this
vasopressor and started on vasopressin although not all patients reached the maximum
rate which reduced the sample size and potential power.
Critical appraisal of the Gordon et al. (2014) study (Appendix F3) showed similar
group demographics and randomization of patients to the two groups. There were two
factors that prevented the two groups from being treated equally. First, due to emergent
situations not all patients received vasopressin as the initial vasopressor. This accounted
for 30% of the study participants who were transitioned over to vasopressin to be
included in the trial. Second, 11 patients did not reach the maximum vasopressin
requirements so did not receive the study drug. In addition, there were five crossovers
from the placebo group to the hydrocortisone group due to refractory shock although
researchers claim the results remained unchanged.
The Lv, Q., Gu, X., Chen, Q., Yu J., & Zheng, R. study (2017) (Appendices D4 &
E4) examined 118 patients with septic shock. The study took place from September 2015
to September 2016 on a 35-bed ICU of the Subei People’s Hospital. The aim was to
assess the importance of early initiation of low dose hydrocortisone. The inclusion
criteria consisted of having an age of 18 years or older and the onset of septic shock
beginning within six hours. Exclusion criteria was receiving corticosteroid therapy
within the last three months, high-dose steroid therapy, presence of immunosuppression,
and refusal of the attending staff or patients’ family. Patient demographics comprised of
a 70/48 male-to-female ratio. Study participants were divided into two groups: the
hydrocortisone group and the placebo group. The hydrocortisone group had a mean age
of 68.8 + 12.6 years and the placebo group was 64.8 + 16.7 years. The mean SOFA
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score for the hydrocortisone group was 11.9 + 3.3 and the placebo group was 9.9 + 3.0.
The intervention comprised of administering 200 mg/dl of hydrocortisone as a continuous
infusion for six days and then tapering it off. Once all vasopressors were discontinued,
the taper protocol was initiated: half dose for five days, then quarter dose for three days,
then stopped. The placebo was normal saline which was administered in the same
manner as the hydrocortisone.
The results of this study (Appendix E4) showed that there were no significant
differences in 28-day or hospital all-cause mortality, length of stay (LOS) in the intensive
care unit (ICU), or hospital between patients treated with hydrocortisone or placebo.
Both the 28-day and hospital all-cause mortality was 39.7% in the hydrocortisone group
and 31.7% in the placebo group. There was a significance level of P=0.365 in both
categories. LOS in the ICU was 10.9 + 17.5 days in the hydrocortisone group while the
placebo group experienced 10.2 + 13.1 days with a significance level of P=0.799. LOS
in the hospital was 23.7 + 36.8 days for the hydrocortisone group and 21.7 + 21.7 days
for the placebo group with a P=0.711 significance level. Early administration of
hydrocortisone enabled earlier titration off vasopressor therapy. Here, the hydrocortisone
group experienced 2.5 + 2.4 days of vasopressor while the placebo group had 2.8 + 4
days (P=0.639). In conclusion, the study demonstrated no decrease in the risk of
mortality or the length of stay in the ICU or hospital with early administration of lowdose hydrocortisone in adults with septic shock. The findings do not support the use of
hydrocortisone in this population.
The critical appraisal of this study (Appendix F4) shows the two groups were not
similar at the start of the trial. The hydrocortisone group started off with a statistically

28

significant (P<0.001) SOFA score that was higher than the placebo group. Also, the
study recruited a small number of patients. The authors pointed out the study was likely
to be underpowered to detect a significant difference by the recruitment of patients with
lower mortality. Despite this, the placebo-controlled, randomized design of the trial
contributes to the validity of the study.
In the Venkatesh et al. (2018) (Appendices D5 & E5) study, the authors examined
whether hydrocortisone reduces mortality among patients with septic shock. This study
recruited a total of 3,800 patients from March 2013 through April 2017. The patients
underwent randomization at 69 med-surg ICUs. The authors compared intravenous
infusions of hydrocortisone with placebo in patients with septic shock who were
undergoing mechanical ventilation in the ICUs. Inclusion criteria required patients to be
older than 18 years of age, on mechanical ventilation, a documented suspicion of
infection, met >2 criteria of the systemic inflammatory response syndrome, and treatment
with vasopressors or inotropic agents for a minimum of 4 hours up to the time of
randomization. The criteria excluding patients from this study were those who were
likely to receive steroids for an indication other than septic shock, had received
etomidate, were considered to likely die from a pre-existing condition within 90 days,
had treatment limitations in place, or had met all the inclusion criteria for more than 24
hours. Of the 3,800 patients randomized, 3,658 were included in the study and were split
into two groups: 1,823 in the hydrocortisone group and 1,826 in the placebo group. The
mean age of the hydrocortisone group was 62.3 + 14.9 years and the placebo group 62.7
+ 15.2 years. There were 60.4% males in the hydrocortisone group and 61.3% in the
placebo group. The median APACHE II score was 24.0 in the hydrocortisone group
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while the placebo group had a score of 23.0. The primary outcome of the study was
death from any cause at 90 days. A secondary outcome was death from any cause at 28
days. The intervention group received 200mg of hydrocortisone per day via a continuous
intravenous infusion over a period of 24 hours for a maximum of seven days or until
discharge from the ICU. The control group received placebo in the same manner as
described.
The results of this study (Appendix E5) demonstrated that septic shock patients
undergoing mechanical ventilation with a continuous hydrocortisone infusion did not
experience a lower 90-day mortality than placebo. The hydrocortisone group had a
27.9% mortality rate while the placebo group was 28.8% (P=0.50). The mortality rate at
28 days did not differ as well between the hydrocortisone and placebo group with rates of
22.3% and 24.3%, respectively (P=0.13). In terms of resolution of shock, it took the
hydrocortisone group 3 days and the placebo group 4 days to resolve shock (P<0.001).
Patients receiving hydrocortisone had a shorter time to ICU discharge needing 10 days
whereas the placebo group required 12 days (P<0.001). The authors noted some
limitations to the trial including the inability to decide on the appropriateness of
prescribed antibiotic therapy and the inability to arbitrate the judgement of the treating
clinicians on adverse effects related to the study. Lastly, data on all possible secondary
infections were not collected.
The critical appraisal (Appendix F5) of the Venkatesh et al. (2018) study revealed
not all patients were accounted for at the end of the trial. This was due to 114 patients
withdrawing or not having informed consent. Also, 28 patients were lost to follow-up.
Regardless of this, the large number of patients provided the study with validity. The
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3,800 originally recruited provided the trial with 90% to detect an absolute difference of
5% in 90-day all-cause mortality.
Annane et al. (2018) (Appendices D6 & E6) conducted a randomized control trial
involving 1,241 patients experiencing septic shock to evaluate the effect of
hydrocortisone and fludrocortisone versus placebo. The trial was conducted from
September 2008 to June 2015 at 34 hospitals. Participants were required to have septic
shock for less than 24 hours. Those excluded from the study had septic shock for at least
24 hours, a high risk of bleeding, pregnancy or lactation, underlying conditions that could
affect long-term survival, or previous treatment with corticosteroids. Participants were
divided into two groups. The hydrocortisone/fludrocortisone group was 65.5 % male
with a mean age of 66 + 14 and a SOFA score of 12 + 3. The placebo group was 67.7%
male with a mean age of 66 + 15, and a SOFA score of 11 + 3. The study’s primary
outcome was 90-day all-cause mortality. Secondary outcomes included all-cause
mortality at ICU discharge, hospital discharge, and day 28, and vasopressor free days by
day 28. The method entailed administering a 50mg bolus of hydrocortisone
intravenously every 6 hours and 50µg of fludrocortisone via a nasogastric tube once daily
every morning. This was given for seven days without tapering. The respective placebos
were given in the same manner.
The main results of the study revealed a 0.88 relative risk of death (95% CI, 0.78
to 0.99) in support of the hydrocortisone/fludrocortisone group. The 90-day all-cause
mortality rate was 43% for this group while the placebo group saw a rate of 49.1%
(P=0.03). In terms of 28-day mortality, there was a 33.7% rate in the intervention group
while the placebo group saw a 38.9% rate P=0.06). Mortality was also significantly

31

lower in the hydrocortisone and fludrocortisone group compared to placebo group at ICU
discharge, 35.4% vs 41% (P=0.04), and hospital discharge, 39% vs 45.3% (P=0.02).
Also, the intervention group witnessed 17 + 11 vasopressor-free days by day 28 while the
placebo group had 15 + 11 days (P<0.001). A key finding that surfaced from the study
was the increased incidence of hyperglycemia in the hydrocortisone and fludrocortisone
group although the risk of secondary infection, GI bleeding, and neurological events were
similar in both groups. The authors did not declare any limitations in this study.
Critical analysis of the Annane et al. (2018) study using CASP (Appendix F6)
found the study met all criteria. The trial had a precise estimate of the treatment effect.
Researchers determined 320 patients were needed in each group to detect an absolute
difference of 10% in 90-day mortality. The study was able to recruit a total of 1,241
patients or about 620 patients in each group.
Cross Analysis
The randomized control trials described were compared and analyzed using the
data collection tables in Appendices D1-6 and E1-6. The tables tracked important data
such as mortality rates, the primary objective of this paper, as well as other common data
like resolution of shock, vasopressor-free days, and LOS in the ICU and hospital. These
results were recorded in Appendix G for cross analysis. Adverse events that occurred in
the studies will also be analyzed.
Participants in all six studies had similar mean ages, gender percentage, and
illness severity using the Sequential Organ Failure Assessment (SOFA) and Acute
Physiology and Chronic Health Evaluation (APACHE II) scores. Mean ages ranged
between 59.3 and 68.8 years and the male gender represented 56-67% of study
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participants among all the studies. Sequential Organ Failure Assessment scores ranged
from 9.0 to 14.6 in the Sprung et al. (2008), Arabi et al. (2010), Lv et al. (2017), and
Annane et al. (2018) studies and APACHE II scores ranged from 19 to 24 in the Gordon
et al. (2014) and Venkatesh et al. (2018) studies which all indicate a high mortality
prediction. The Arabi et al. (2010) study used only patients with liver cirrhosis. This
may have led to the high mortality rate among all the studies. Despite this, there was still
no significant difference in 28-day mortality between the two study groups, with the
hydrocortisone group having an 85% rate and the placebo group a 72% rate (P=0.19.)
The Venkatesh et al. (2018) study included only mechanically ventilated patients within
their participants whereas the other studies did not exclude non-ventilated participants.
This study also specifically excluded patients who had received etomidate as it was noted
the drug has adrenal-suppressant properties. All other studies did not exclude patients
who received this drug. In the end, mortality rates remained similar, with the
hydrocortisone group exhibiting a 22.3% rate and placebo group a 24.3% rate (P=0.13).
Five of the six randomized control trials, Sprung et al. (2008), Arabi et al. (2010),
Gordon et al. (2014), Lv et al. (2017), and Venkatesh et al. (2018), showed there was no
significant difference between corticosteroid and placebo groups in 28-day mortality
(Appendix G). Only one randomized control trial, the Annane et al. (2018) study,
showed a decrease in mortality at day 28 in the corticosteroid group compared to the
placebo group. Here, the mortality at day 28 was 33.7% for the corticosteroid group and
38.9% for the placebo group (P=0.06).
There were some variances among the studies in terms of the secondary
endpoints. In terms of resolution of shock, there was faster shock reversal in the
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corticosteroid group in the Arabi et al. (2010) and Venkatesh et al. (2018) studies. Arabi
et al. (2010) showed 62% of patients in the corticosteroid group demonstrated resolution
of shock compared to 39% in the placebo group (P=0.05). In the Venkatesh et al. (2018)
study, shock resolved one day earlier in the corticosteroid group (P=<0.001). There were
no differences in reversal of shock the Sprung et al. (2008) study (79.7% vs 74.2%) and
in the Lv et al. (2017) study (65.6% vs 70.0%, P=0.602). However, the median time until
reversal of shock was shorter in the corticosteroid group in the Sprung et al (2008) study:
3.3 days in the corticosteroid group compared to 5.28 days in the placebo group. The
other studies did not report this endpoint.
Four studies, Arabi et al. (2010), Gordon et al. (2014), Lv et al. (2017), and
Annane et al. (2018), exhibited more vasopressor-free days or less days on a vasopressor
in the hydrocortisone group than the placebo group. The most significant result was in
the Gordon et al. (2014) study in which the corticosteroid group demonstrated a 3.1day
shorter duration of vasopressor therapy than the placebo group (P=0.001). The Lv et al.
(2017) study had the corticosteroid group on 2.5 + 2.4 days of vasopressor whereas the
placebo group was 2.8 + 4 days (P=0.639). Arabi et al. (2010) reported 6.8 vasopressorfree days in the corticosteroid group versus 5.6 days in the placebo group (P=0.54). The
study by Annane et al. (2018) reported that the corticosteroid group had 17 + 11
vasopressor-free days compared to 15 + 11 days in the placebo group (P<0.001). The
remaining two studies did not report this secondary endpoint.
There was no difference in LOS in the ICU or hospital in the Sprung et al. (2008),
Arabi et al. (2010), and Lv et al. (2017) studies. Venkatesh et al. (2018) reported a
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shorter time to ICU discharge in the hydrocortisone group (P<0.001). This secondary
endpoint was not reported by Gordon et al. (2014) or Annane et al. (2018).
The most common adverse event attributed to the use of corticosteroids was
hyperglycemia. This was documented in the randomized control trials by Sprung et al.
(2008), Arabi et al. (2010), Venkatesh et al. (2018), and Annane et al. (2018). Other
more prominent adverse events included superinfection and hypernatremia in Sprung et
al. (2008) as well as gastrointestinal bleeding in Arabi et al. (2010). The Lv et al. (2017)
study did not report adverse events and the study by Gordon et al. (2016) could not
attribute the adverse events as a result of corticosteroid use.
There existed differences among the studies that may have influenced the end
results. There were some differences in type of corticosteroid and administration method.
Although five studies, Sprung et al. (2008), Arabi et al. (2010), Gordon et al. (2014), Lv
et al. (2017), and Venkatesh et al. (2018), used the same corticosteroid, hydrocortisone,
the dosages and timing of administration may have varied. Sprung et al. (2008) and
Gordan et al. (2014) used 50 mg dosage boluses and the same administration method and
the drug was tapered after five days. Arabi et al. (2010) used the same dosage, although
tapering only occurred once shock was resolved. Lv et al. (2017) and Venkatesh et al.
(2018) used the same dosage of 200 mg/d as a continuous infusion. Lv et al. (2017)
tapered the drug once vasopressors were discontinued whereas Venkatesh et al. (2018)
discontinued it after seven days or at ICU discharge. The study conducted by Annane et
al. (2018) used fludrocortisone in addition to hydrocortisone. The hydrocortisone was
administered as a 50 mg intravenous bolus every 6 hours and fludrocortisone was given
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as a 50 µg tablet through a nasogastric tube once daily in the morning. These were
administered for seven days without tapering.
The study by Gordon et al. (2016) had a key difference in treatment method that
could have impacted end results. The Gordon et al. (2016) study was the only study that
did not use norepinephrine as the primary vasopressor. Here, vasopressin was used as the
primary vasopressor instead of norepinephrine. Although vasopressin is not
recommended as the initial vasopressor in septic shock, one of the primary objectives in
this study was to test the interaction between vasopressin and corticosteroids. All other
treatment was based on the Surviving Sepsis Campaign Guidelines at the time the study
was conducted.
Next, summary and conclusions will be addressed.

36

Summary and Conclusions
Sepsis is a major concern in hospitals that results in a high mortality (Center for
Disease Control [CDC)], 2017) and increased health care costs (Pfuntner, Weir, &
Steiner, 2013). Its most severe form, septic shock, has been the focus of groups such as
the Surviving Sepsis Campaign. A widely used adjunctive in the treatment of septic
shock is corticosteroids. The use of intravenous corticosteroids has been thought to
improve the insufficient adrenal function of critically ill patients experiencing septic
shock (Gupta & Ba, 2008). There have been disagreements on the efficacy of
corticosteroids in decreasing mortality in septic shock patients (Lv et al., 2017). The
Surviving Sepsis Campaign has cited corticosteroid use as a weak recommendation due
to contradictory results of prior studies showing either reduction or no difference in
mortality rates (Rhodes et al., 2017). Since the latest recommendation in 2016, studies
have been published that may provide new evidence on the effects of corticosteroids on
mortality in adult patients with septic shock. Furthermore, the widespread use of the
guidelines by medical care providers in hospitals has decreased variances in treatment
methods that may have existed in past randomized control trials.
The purpose of this systematic review was to examine whether the use of
corticosteroids in septic shock impacts overall mortality in adult patients. The CINAHL,
PubMed, OVID, and Cochrane Library databases were used to conduct a comprehensive
search on this topic. The PRISMA 27-item checklist and four-phase diagram (Moher et
al., 2009) were utilized in the search process to ensure a thorough selection of studies.
This search strategy ultimately resulted in six randomized control trials to be used in this
systematic review. Pertinent data was extracted and organized using two data collection
tables produced by this author (Appendices D1-6 and E1-6). The quality of each study
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was assessed using the Critical Appraisal Skills Programme (CASP) Randomized Control
Trial Checklist (Appendix F). Cross analysis of the studies was conducted utilizing the
chart depicted in Appendix G. This chart recorded the primary objective of mortality rate
at day 28 as well as the secondary endpoints of resolution of shock, vasopressor usage,
and length of stay in the ICU and hospital.
The randomized control trials conducted by Sprung et al. (2008), Arabi et al.
(2010), Gordon et al. (2014), Lv et al. (2017), and Venkatesh et al. (2018) showed
corticosteroids did not have an effect on mortality in adult patients with septic shock.
There was no significant difference between corticosteroid and placebo groups in 28-day
mortality (Appendix G). The Annane et al. (2018) study was the only one of the six
studies that demonstrated a decrease in mortality at day 28 in the corticosteroid group
compared to the placebo group. The most significant difference between these two
conflicting results was that the Annane et al. (2018) study utilized fludrocortisone in
addition to hydrocortisone. The other studies used only hydrocortisone as the drug of
choice. It is important to note there existed some variations among the studies: Arabi et
al. (2010) used only patients with cirrhosis; Gordon et al. (2014) used vasopressin instead
of norepinephrine as the primary vasopressor; and Venkatesh et al. (2018) used only
patients who were ventilated and did not receive etomidate. Even with these differences
among studies, each study’s intervention and control groups were alike regarding patient
characteristics and both groups received the same treatment method.
There was faster shock reversal in patients receiving corticosteroids in the Arabi
et al. (2010) and Venkatesh et al. (2018) studies. Sprung et al. (2008) and Lv et al.
(2017) did not find a significant difference in the two groups, although Sprung et al.
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(2008) did report a shorter median time until reversal of shock in the corticosteroid
group. The remaining studies did not report this endpoint. Results of four studies by
Arabi et al. (2010), Gordon et al. (2014), Lv et al. (2017), and Annane et al. (2018)
displayed more vasopressor-free days or less days on a vasopressor in the hydrocortisone
group than the placebo group. The other two studies did not investigate this endpoint. In
terms of LOS in the ICU or hospital, the Sprung et al. (2008), Arabi et al. (2010), and Lv
et al. (2017) studies did not find any difference among the two study groups. The only
significant finding was attained by Venkatesh et al. (2018); these authors reported a
shorter time to ICU discharge in the hydrocortisone group. This secondary endpoint was
not studied in the Gordon et al. (2014) or Annane et al. (2018) trials. The action of
corticosteroids on patient’s suppressed HPA axis could explain the quicker resolution of
shock and decreased vasopressor usage in the corticosteroid groups of the studies. Their
anti-inflammatory properties may assist in reducing shock time. Also, corticosteroids’
effects of increasing the body’s sensitivity to catecholamines, like norepinephrine, may
decrease time and amount of vasopressor usage.
The most common adverse event attributed to the use of corticosteroids was
hyperglycemia. This was documented in the randomized control trials by Sprung et al.
(2008), Arabi et al. (2010), Venkatesh et al. (2018), and Annane et al. (2018). Other
more prominent adverse events included superinfection and hypernatremia in Sprung et
al. (2008) as well as gastrointestinal bleeding in Arabi et al. (2010). The Lv et al. (2017)
study did not report adverse events and the study by Gordon et al. (2016) could not
attribute the adverse events as a result of corticosteroid use. These adverse events could
possibly have occurred in patients with high risk conditions. A patient with a history of
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uncontrolled diabetes or with multiple gastrointestinal bleedings may have a higher
propensity of these adverse events occurring when receiving corticosteroids. The studies
did not provide information on whether these events occurred in such patients.
There existed some limitations in this systematic review. First, there were only
six studies that met the inclusion and exclusion criteria, which may affect
generalizability. Second, although the primary aim of researching mortality was
achieved, not all studies reported the same secondary endpoints. There also existed
limitations among the six studies in this systematic review. Some studies (Arabi et al.,
2010; Lv et al., 2017) reported a single center setting which may affect generalizability.
Three studies (Sprung et al., 2008; Gordon et al., 2014; Lv et al., 2017) reported a small
sample size resulting in a limited power to detect differences in the measured clinical
outcomes. All the studies reported power except Lv et al. 2017. Here, the authors
believed the study to be underpowered based on the recruitment of patients with lower
mortality (original sample size calculation based on control mortality of 60%, but their
study’s control 28-day mortality was almost half). The Arabi et al. (2010) study did not
achieve their intended sample size, although they did not report this as a limitation. The
limited power in these studies may affect generalizability as well. This means these trials
demonstrated no significant difference between the groups being studied or they failed to
detect a difference due to the lack of power. The Sprung et al. (2008) and Gordon et al.
(2014) studies stated there were crossovers from the placebo group to the hydrocortisone
group, meaning these patients received open-label corticosteroids. The authors stated
that this was unlikely to have an effect on the outcomes.
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Despite the limitations mentioned, this systematic review provided sufficient
evidence to draw a conclusion. The majority of studies in the systematic review did not
show an impact on overall mortality between the use of corticosteroids and placebo in
adult patients with septic shock. The limitations previously mentioned must be taken into
consideration. The four studies that were under-powered could have failed to detect a
difference between the corticosteroid and placebo groups. Also, two studies used a single
center setting to conduct their trial. The generalizability should be applied with caution
considering these two factors. Further studies that are adequately powered using multiple
centers are required in order to provide more statistically significant data and clinical
importance. Future studies with a power of 80% would be sufficient considering any rise
in power could be difficult since it would require increased sample sizes and study costs.
Additional studies using fludrocortisone should be conducted as well. The study by
Annane et al. (2018) was the only study that used this corticosteroid in addition to
hydrocortisone and the only study demonstrating a decrease in mortality rates. In spite of
these results, fludrocortisone cannot be singly attributed to decreased mortality rates.
More studies using this corticosteroid, while also using adequate power and multiple
centers, would provide supplemental data on the impact of corticosteroids on mortality in
adult patients experiencing septic shock.
The achievement of the primary aim in this systematic review in combination
with the comparison of the secondary endpoints results in recommendations and
implications that can be made for the advanced practice nurse in the clinical setting.
Recommendations and implications for advanced practice will be discussed in the next
section.
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Recommendations and Implications for Advanced Nursing Practice
Septic shock is a condition with a high mortality rate and high cost for healthcare
institutions. Advanced practice nurses (APNs) are increasingly becoming an integral part
of healthcare teams. It should be an expectation for all APNs to stay informed on the
most current evidence-based results and incorporate them into their practice. This review
was able to contribute to evidence-based knowledge and provided an opportunity to guide
APNs in making more informed decisions.
The results of this systematic review demonstrate that the use of corticosteroids in
patients with septic shock cannot be strongly recommended. Five of the six studies in the
review showed no improvement in mortality in this population; only one study by
Annane et al. (2018) showed a decrease in mortality. It is important to note that mortality
did not increase in any study and therefore the use of corticosteroids should not be
disregarded as an option when managing care for a patient with septic shock. Advanced
practice nurses should take this into consideration when contemplating using
corticosteroids in patients with septic shock.
This systematic review generated valuable information and evidence on whether
the use of corticosteroids in septic shock impacts overall mortality in adult patients. The
review shed light on the latest results of randomized control trials on this topic. Current
practice leaves it up to the discretion of the provider to use corticosteroids in this patient
population. It is sometimes used as a last-ditch effort to save the patient when
hemodynamic parameters fail to improve with other interventions. The information from
this systematic review can be utilized to potentially improve the care that APNs provide
as well as to teach student and novice nurse practitioners. The APN should be aware of
the limitations of this systematic review and the research studies, as mentioned
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previously, that affect generalizability. Nevertheless, the use of the latest research should
guide the APN in making informed decisions and should be the standard in which care is
provided.
The secondary outcomes also need to be considered. Advanced practice nurses
need to be cognizant of the adverse events that could occur with corticosteroid
administration. Patients with past medical histories of brittle diabetes, gastrointestinal
bleeding or hypernatremia likely would potentially suffer from worse outcomes if given
corticosteroids. One must be mindful of these unique patient characteristics so that the
appropriate care can be optimized. Caution should be taken in such patients as
administration of corticosteroids would require closer monitoring and may necessitate
additional resources. For example, when using corticosteroids, an insulin drip may be
required for labile glucoses in patients with diabetes. Being able to recognize these
differences and applying research results when suitable is the critical thinking that should
be expected of APNs.
The resolution of shock and decreased vasopressor use could be an incentive in
using corticosteroids. Furthermore, the possibility of decreased length of stay in the
intensive care unit and hospital are other benefits. Venkatesh et al. (2018) mention the
overall cost-effectiveness of hydrocortisone in patients with septic shock should be
assessed. This would align with healthcare’s recent approaches in providing better care
at a lower cost. More research needs to be conducted to provide additional data regarding
this topic.
Advanced practice nurses are in prime position to be a part of research teams to
investigate further the effect of corticosteroids on mortality in septic shock patients. The
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limitations described earlier identify areas in which future studies can be improved: larger
sample sizes with adequate power and more centers used. The limitations also provide an
area requiring further investigation which is the effect of fludrocortisone on mortality in
this selected patient population. Other areas of research include focusing on the
relationship between corticosteroid use and shock reversal, vasopressor use, or ICU and
hospital length of stay. Qualitative research questions could also be explored, such as
differences in patient and family satisfaction with hospitalization after corticosteroid use
or patient’s perception of quality of life. Septic shock guideline adherence by providers
is another area of qualitative research that could be investigated. The APN can be
involved in conducting such research that could deliver key data resulting in changes in
clinical practice.
The information from this systematic review also has implications for education
and training. The education and training of future APNs should embrace the most current
research available. Informing students of results such as those presented in this review
will deliver fundamental information that shapes practice.
Results of this review should also be discussed with staff nurses and other
members of the interdisciplinary team. Staff nurses spend more time at the patient’s
bedside than any other provider. Staff nurses who are aware of the potential risk of
adverse events can provide more vigilance during corticosteroid administration and
thereby alert the medical team to minimize the effects of adverse events or prevent them
from occurring.
Current guidelines recommend corticosteroids in septic shock patients only if
hemodynamics stability is not achieved with fluid resuscitation or vasopressors. The
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review of the most recent randomized control trials included in this systematic review
does not suggest changes be made to this recommendation. These results should be used
as a supplemental resource to assist the APN in clinical decision making. Advance
practice nurses should also be attentive to the factors the lead to septic shock. This
attention to clinical prevention has the potential to greatly reduce the number of patients
who develop this deadly condition. Policies regarding central line-associated blood
stream infections, catheter-associated blood stream infections, and surgical site infections
should be carefully followed. Adhering to guidelines on the management of conditions
such as pneumonia, burns, and acute pancreatitis can also prevent development of septic
shock. It is important to prevent infections in patients with weakened immune systems
such as those receiving long-term steroid treatment and chemotherapy as well as patients
with long-term health conditions like diabetes and cirrhosis. Being aware of these patient
populations and providing appropriate teaching can prevent sepsis that could eventually
lead to septic shock.
Septic shock is a condition that has detrimental effects on patients and healthcare
overall. Measures must be taken to prevent mortality and any negative consequences that
may result. Awareness of the latest research on the impact of corticosteroids on mortality
in adult patients with septic shock contributes to the knowledge APNs require to improve
and deliver the best care for their patients.
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(Moher et al., 2009)

50

Appendix B
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Appendix D
D1: Data Collection Tool 1

Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., … Briegel, J. (2008). Hydrocortisone therapy
for patients with septic shock. The England Journal of Medicine, 358(2), 111-124.
Purpose

Study Design

Sample Demographics

Mortality Endpoint Corticosteroid

To evaluate the
efficacy and safety of
low-dose
hydrocortisone in
patients with septic
shock – in particular,
patients who had a
response to a
corticotropin test.

Multicenter, randomized,
double-blind, placebocontrolled study.

500 patients enrolled,
although 1 withdrew
consent. Divided into 2
groups: hydrocortisone
group (251 patients) and
placebo group (248
patients).

The primary
endpoint was death
at 28 days in
patients who did
not have a
response to
corticotropin.

Patients were enrolled from
March 2002 to November 2005
at 52 ICUs in 9 countries.
Inclusion criteria: 18 years or
older, clinical evidence of
infection, evidence of a
systemic response to infection,
the onset of shock within the
previous 72 hours, and
hypoperfusion or organ
dysfunction attributable to
sepsis.
Exclusion criteria: underlying
disease with a poor prognosis, a
life expectancy of less than 24

Mean age: hydrocortisone
group = 63 + 14, placebo
group = 63 + 15.

Secondary
endpoints included
rates of death at 28
days in patients
Male gender:
who had a
hydrocortisone group =
response to
166 (66%), placebo group
corticotropin and
= 166 (67%).
overall, in the
ICU, in the
SOFA score:
hospital, the rate of
hydrocortisone group =
shock reversal, and
10.6 + 3.4, placebo group = LOS in the ICU
10.6 + 3.2.
and hospital.

Hydrocortisone
was given as a 50
mg bolus
intravenously
every 6 hours for 5
days, then tapered
to 50 mg every 12
hours for days 6 to
8, 50 mg every 24
hours for days 9 to
11, and then
stopped.
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Purpose

Study Design
hours, immunosuppression, and
treatment with long-term
corticosteroids within the past 6
months or short-term
corticosteroids within the last 4
weeks.

Sample Demographics

Mortality Endpoint Corticosteroid
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D2: Data Collection Tool 1

Arabi Y. M., Aljumah A., Dabbagh O., Tamim H. M., Rishu A. H., Al-Abdulkareem, A., … Cherfan A. (2010). Low-dose
hydrocortisone in patients with cirrhosis and septic shock: A randomized controlled trial. Canadian Medical Association Journal,
182(18), 1971-7. doi: 10.1503/cmaj.090707
Purpose
Study Design
Sample Demographics
Mortality Endpoint Corticosteroid
Examine the effect of
low-dose
hydrocortisone in
patients with cirrhosis
who presented with
septic shock.

Randomized double-blind
placebo-controlled trial.
900-bed tertiary care academic
hospital on a 21-bed medicalsurgical ICU.
Inclusion criteria: patients aged
18 years or older with liver
cirrhosis who presented with
septic shock within 72 hours of
the onset of hypotension.
Exclusion criteria: hemorrhagic
shock, known adrenal
insufficiency, any prior
systemic steroid usage,
contraindications for systemic
steroids, post-cardiac arrest, and
do-not-resuscitate status.
Full dose of study drug was
continued until shock

140 patients screened, 75
enrolled and randomly
allocated. 60 patients were
enrolled within 24 hours
after the onset of shock and
71 within 48 hours.
Mean age: hydrocortisone
group = 60.6 + 12.6,
placebo group = 59.3 +
12.2
Female(%): hydrocortisone
group = 17(44%), placebo
group = 16(44%)
Mean SOFA score:
hydrocortisone group =
14.6 + 3.7, placebo group =
14.3 + 3.7

The primary
outcome was 28day all-cause
mortality.
Secondary
outcomes included
ICU-specific and
hospital-specific
mortality, shock
reversal, and
vasopressor-free
days.

Participants
received
intravenous bolus
injections every
six hours of 5 mL
of normal saline
containing 50 mg
of hydrocortisone
Once shock
resolved, the dose
was reduced by 1
mL every 2 days
until
discontinuation.
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Purpose

Study Design
resolution, which was defined
as blood pressure stability
(MAP>65) without
vasopressors for 24 hours.

Sample Demographics

Mortality Endpoint Corticosteroid
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D3: Data Collection Tool 1

Study: Gordon, A. C., Mason, A. J., Perkins, G. D., Stotz, M., Terblanche, M., Ashby, D., & Brett, S. J. (2014). The interaction of
vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Critical Care Medicine 42(6), 1325-1333.
Purpose

Study Design

Sample Demographics

Mortality Endpoint Corticosteroid

To test for an
interaction between
vasopressin and
corticosteroids in
septic shock.

Prospective open-label
randomized controlled pilot
trial.

61 adult patients who had
septic shock.

The primary
outcome was the
difference in
plasma
vasopressin
concentration
between the two
groups.

Conducted between October
2010 and March 2012 at four
adult ICUs in London teaching
hospitals.
Inclusion criteria: adult patients
(>16 yrs) who had septic shock
requiring vasopressors despite
adequate IV fluid resuscitation.
Exclusion criteria: patients who
received a previous continuous
infusion of vasopressors during
current hospitalization, an
ongoing requirement for
systemic steroids, end-stage
renal failure, known mesenteric
ischemia, Raynaud’s
phenomenon, systemic sclerosis

Male gender:
hydrocortisone group =
58%, placebo group =
60%.
Mean age: hydrocortisone
group = 61, placebo group
= 60.
Mean APACHE II score:
hydrocortisone group = 19,
placebo group = 20.

Secondary
outcomes included
28-day, ICU, and
hospital mortality.

Hydrocortisone
phosphate was
given as a 50mg
IV bolus every 6
hours for 5 days,
every 12 hours for
3 days, and then
once daily for 3
days.
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Purpose

Study Design
or other vasospastic disease,
ongoing treatment for an acute
coronary syndrome, death
anticipated within 24 hours,
known pregnancy,
hypersensitivity to any study
drugs, or enrollment in another
trial that may interact with
study drugs.
Patients were assigned to one of
two groups: vasopressin and
hydrocortisone or vasopressin
and placebo.
All patients were planned to
receive vasopressin (titrated to
0.06U/min as the initial
vasopressor. Once max infusion
rate reached, patients received
either hydrocortisone or
placebo.

Sample Demographics

Mortality Endpoint Corticosteroid
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D4: Data Collection Tool 1

Lv, Q., Gu, X., Chen, Q., Yu J., & Zheng, R. (2017). Early initiation of low-dose hydrocortisone treatment for septic shock in
adults: A randomized clinical trial. American Journal of Emergency Medicine, 35(12), 1810-1814.
doi: 10.1016/j.ajem.2017.06.004
Purpose

Study Design

Sample Demographics

Mortality Endpoint Corticosteroid

To assess the
importance of early
initiation of low dose
hydrocortisone.

A placebo-controlled,
randomized clinical trial.

118 patients
Gender: male/female =
70/48

28-day mortality

From Sept 2015 to Sept 2016,
118 patients admitted to the 35bed ICU of the Subei People’s
Hospital were recruited.
Inclusion criteria: age 18 yrs or
older, onset of septic shock
within 6 hours.
Exclusion criteria: systemic
corticosteroid therapy within
the last 3 months, high-dose
steroid therapy,
immunosuppression, refusal of
the attending staff or patient
family.

Age (mean + SD):
hydrocortisone group =
68.8 + 12.6,
placebo group = 64.8 +
16.7
SOFA score (mean + SD):
hydrocortisone group =
11.9 + 3.3, placebo group =
9.9 + 3.0

Hydrocortisone
administered 200
mg/d as a
continuous
infusion for 6
days, then tapered
off. Once all
vasopressors
discontinued, the
taper protocol was
initiated (half dose
for 5 days, then
quarter dose for 3
days, then
stopped)
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D5: Data Collection Tool 1

Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., … Myburgh, J. (2018). Adjunctive
glucocorticoid therapy in patients with septic shock. The New England Journal of Medicine, 379(9), 797-808.
Purpose

Study Design

Sample Demographics

Mortality Endpoint Corticosteroid

To determine whether
hydrocortisone
reduces mortality
among patients with
septic shock.

Investigator-initiated,
international, pragmatic,
double-blind, parallel-group,
randomized controlled trial.

3,658 enrolled patients:
1,832 in hydrocortisone
group, 1,826 in placebo
group.

Primary outcome
was death from
any cause at 90
days.

From March 2013 through
April 2017, a total of 3,800
patients underwent
randomization at 69 med-surg
ICUs.

Age (mean + SD):
hydrocortisone group =
62.3 + 14.9,
placebo group = 62.7 +
15.2

Death from any
cause at 28 days
was a secondary
outcome.

Compared intravenous
infusions of hydrocortisone
with matched placebo in
patients with septic shock who
were undergoing mechanical
ventilation in an ICU.

Male gender:
hydrocortisone group =
60.4%, placebo group =
61.3%

Inclusion criteria: Adults (>18
years), undergoing mechanical
ventilation, documented
suspicion of infection, met >2
criteria of the systemic

APACHE II median score:
hydrocortisone group =
24.0, placebo group = 23.0

Hydrocortisone at
a dose of 200mg
per day
administered by
means of
continuous
intravenous
infusion over a
period of 24 hours
for a maximum of
7 days or until ICU
discharge.
Masked vial
reconstituted to
produce a
concentration of
1mg per milliliter.

60

Purpose

Study Design
inflammatory response
syndrome, and who had been
treated with vasopressors or
inotropic agents for a minimum
of 4 hours up to and at the time
of randomization.
Exclusion criteria: If patients
were likely to receive
glucocorticoids for an
indication other than septic
shock, had received etomidate,
were considered to be likely to
die from a pre-existing disease
within 90 days, had treatment
limitations in place, or had met
all the inclusion criteria for
more than 24 hours.

Sample Demographics

Mortality Endpoint Corticosteroid
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D6: Data Collection Tool 1
Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J. P., Siami, S., … Bellissant, E. (2018). Hydrocortisone plus
fludrocortisone for adults with septic shock. New England Journal of Medicine, 378(9), 809-818.
doi: 10.1056/NEJMoa1705716
Purpose

Study Design

Sample Demographics

Mortality Endpoint Corticosteroid

To evaluate the effect
of hydrocortisone plus
fludrocortisone
therapy versus placebo
in patients with septic
shock.

A multicenter, double-blind,
randomized trial with twogroup parallel design.

1,241 patients: 626
hydro/fludro group, 614
placebo group

90-day all-cause
mortality.

(Originally purpose
was to evaluate effect
of hydrocortisone plus
fludrocortisone
therapy, drotrecogin
alpha, the combination
of the three drugs, or
their respective
placebos but
drotrecogin alpha
removed from market
during trial).

34 participating centers.
Patients recruited from Sept 2,
2008 through June 23, 2015.

Age (mean + SD):
hydrocortisone group = 66
+ 14, placebo group = 66 +
15

Inclusion criteria: indisputable
or probable septic shock for less Male gender: hydro/fludro
than 24 hours.
group = 402 (65.5%),
placebo group = 424
Exclusion criteria: presence of
(67.7%)
septic shock for at least 24
hours, a high risk of bleeding,
SOFA score: hydro/fludro
pregnancy or lactation,
group = 12 + 3, placebo
underlying conditions that could group = 11 + 3
affect short-term survival, or
previous treatment with
corticosteroids.

Secondary
outcomes included
all-cause mortality
at ICU discharge,
hospital discharge,
and day 28, and
vasopressor free
days by day 28.

Hydrocortisone
was administered
as a 50-mg
intravenous bolus
every 6 hours, and
fludrocortisone
was given as a 50µg tablet through a
nasogastric tube
once daily in the
morning. This was
administered for 7
days without
tapering.
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Appendix E
E1: Data Collection Tool 2

Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., … Briegel, J. (2008). Hydrocortisone therapy
for patients with septic shock. The England Journal of Medicine, 358(2), 111-124.
Identified Placebo Mortality Rate at Day 28

Exact placebo not
mentioned. Vials
containing
placebo were
identical to those
containing
hydrocortisone.

Corticosteroid

Placebo
(No corticosteroid)

86 (34.3%)

78 (31.5%)

Key Findings

Limitations

There was no significant
difference between the two
study groups in the rate of
death at 28 days among overall
patients and those with and
without a response to
corticotropin.

Authors note a lack of adequate power
since only 500 patients were enrolled
instead of the projected 800. They
attributed this to slow recruitment,
termination of funding, and expiration
date of the trial drug.

Overall: hydrocortisone group
= 34.3% (95% CI., 28.3 to
40.2), placebo group = 31.5%
(95%, 25.5 to 37.3; P = 0.51).
No corticotropin response:
hydrocortisone group = 39.2%
(95% CI, 30.5 to 47.9),
placebo group = 36.1% (95%
CI, 26.9 to 45.3; P=0.69).

21 patients received open-label
corticosteroids (4.2%). Authors
believed this was unlikely to have an
effect on the outcome.
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Identified Placebo Mortality Rate at Day 28
Corticosteroid

Key Findings

Placebo
(No corticosteroid)

Corticotropin response:
hydrocortisone group = 28.8%
(95% CI, 20.6 to 37.0),
placebo group = 28.7% (95%
CI, 21.2 to 36.3; P = 1.00).
ICU discharge 28-day
mortality: hydrocortisone
group = 40.6%, placebo group
= 36% (P=0.31).
Hospital discharge 28-day
mortality: hydrocortisone
group = 44.6%, placebo group
= 40.8 (P=0.47).
Reversal of shock was similar
among all patients.
Hydrocortisone group =
79.7%, placebo group = 74.2%
(P=0.18).
Median time until reversal of
shock was shorter in the
hydrocortisone group:
hydrocortisone group = 3.3
days, placebo group = 5.28
days.

Limitations
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Identified Placebo Mortality Rate at Day 28
Corticosteroid

Key Findings

Placebo
(No corticosteroid)

LOS was similar in both
groups.
In ICU: hydrocortisone group
= 19 + 31, placebo group = 18
+ 17 (P=0.51).
In hospital: hydrocortisone
group = 34 + 41, placebo
group = 34 + 37 (P=0.47).
In the hydrocortisone group
there was an increased
incidence of superinfections
(new episodes of sepsis or
septic shock), hyperglycemia,
and hypernatremia.

Limitations
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E2: Data Collection Tool 2

Arabi Y. M., Aljumah A., Dabbagh O., Tamim H. M., Rishu A. H., Al-Abdulkareem, A., … Cherfan A. (2010). Low-dose
hydrocortisone in patients with cirrhosis and septic shock: A randomized controlled trial. Canadian Medical Association Journal,
182(18), 1971-7. doi: 10.1503/cmaj.090707
Identified Placebo Mortality Rate at Day 28
Corticosteroid

Normal saline
33 (85%)
(placebo) given in
same manner as
hydrocortisone.

Key Findings

Limitations

There was no significant
difference between the
hydrocortisone and placebo
groups in 28-day mortality (33
[85%] v. 26 [72%], RR 1.117,
95% CI 0.92-1.49, p=0.19).

Limitations included the setting of the
study at a single-centre which may
affect its generalizability.

Placebo
(No corticosteroid)

26 (72%)

The length of the randomization
window was long at 72 hours.

There was no difference
Etomidate was used in some patients
between the two groups in ICU which has been shown to cause adrenal
(P=0.86) or hospital LOS
suppression.
(P=0.90).
ICU mortality was 24 (62%) in
hydrocortisone group and 24
(67%) in placebo group
(P=0.64).
Hospital mortality was 34
(87%) in hydrocortisone group
and 32 (89%) in placebo group
(P=0.82).
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Identified Placebo Mortality Rate at Day 28
Corticosteroid

Key Findings

Placebo
(No corticosteroid)

The hydrocortisone showed
improved hemodynamic
parameters.
Shock reversal: hydrocortisone
group = 24 (62%), placebo
group 14 (39%) (P=0.05).
Mean vasopressor-free days:
hydrocortisone group = 6.8,
placebo group = 5.6 (P=0.54).
Hydrocortisone was associated
with higher rates of severe
hyperglycemia: hydrocortisone
group = 34 (87%), placebo
group = 25 (69%).
Also, there was a significant
increase in the risk of
gastrointestinal bleeding:
hydrocortisone group = 13
(33%), placebo group = 4
(11%).

Limitations
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E3: Data Collection Tool 2

Gordon, A. C., Mason, A. J., Perkins, G. D., Stotz, M., Terblanche, M., Ashby, D., & Brett, S. J. (2014). The interaction of
vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Critical Care Medicine 42(6), 1325-1333.
Identified Placebo Mortality Rate at Day 28

Placebo was 0.5
mL 0.9% saline
given in same
manner as
hydrocortisone.

Corticosteroid

Placebo
(No corticosteroid)

7 (23%)

7 (23%)

Key Findings

Limitations

There was no difference in
mortality rates.
28-day mortality:
hydrocortisone group = 23%,
placebo group = 23% (-0.01*).
ICU mortality: hydrocortisone
group = 23%, placebo group =
27% (-0.04*).
Hospital mortality:
hydrocortisone group = 26%,
placebo group = 30% (-0.04*).
*Difference in proportions:
(vaso + hydro) – (vaso +
placebo).

The study was prospectively powered
to detect a difference in plasma
vasopressin levels at single point after
reaching maximum rate of vasopressin
infusion and corticosteroid
administration. Not all patients reached
the max vasopressin rate even though
additional existing catecholamines
were weaned off quickly. This reduced
the sample size and potential power in
the analysis of plasma levels

Patients in the hydrocortisone
group were weaned off
vasopressin more quickly with
a 3.1 day (P=0.001) shorter
duration of vasopressin
infusion and a halving of the

There were 5 crossovers from the
placebo group to hydrocortisone group
due to refractory shock (although
results remained unchanged).
The use of 61 patients resulted in
limited power to detect differences in
clinical outcomes measures.
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Identified Placebo Mortality Rate at Day 28
Corticosteroid

Key Findings

Placebo
(No corticosteroid)

total dose (P=0.001) of
vasopressin required than
placebo group. Hydrocortisone
= 2.5 + 2.4 days of
vasopressor, placebo group =
2.8 + 4 days.
There was no difference in
plasma vasopressin levels.
14 adverse events reported
although none attributed
directly to hydrocortisone.

Limitations
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E4: Data Collection Tool 2

Lv, Q., Gu, X., Chen, Q., Yu J., & Zheng, R. (2017). Early initiation of low-dose hydrocortisone treatment for septic shock in
adults: A randomized clinical trial. American Journal of Emergency Medicine, 35(12), 1810-1814.
doi: 10.1016/j.ajem.2017.06.004
Identified Placebo Mortality Rate at Day 28

Normal saline
(Administration
procedure same
as
hydrocortisone)

Corticosteroid

Placebo
(No corticosteroid)

23 (39.7%)

19 (31.7%)

Key Findings

Limitations

There were no significant
differences in 28-day
(P=0.365) or hospital all-cause
mortality length of stay in the
ICU or hospital between
patients treated with
hydrocortisone or placebo.

Only short-term outcomes, 28-day and
in-hospital mortality, were collected
and therefore any long-term difference
between treatment groups cannot be
assessed.

In-hospital mortality:
hydrocortisone group = 23
(39.7%),
placebo group = 19 (31.7%,
P=0.365)
LOS in ICU, days:
hydrocortisone group = 10.9 +
17.5,
placebo group = 10.2 + 13.1
(P=0.799)

The study was likely to be
underpowered to detect a statistically
significant difference by the
recruitment of patients with lower
mortality. Authors note the original
calculated sample size was based on a
control mortality of 60% using findings
from a large prior study, but this
study’s control mortality was about
half.
The sample size was relatively small,
and only one center was involved,
which may affect its generalizability.
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Identified Placebo Mortality Rate at Day 28
Corticosteroid

Key Findings

Placebo
(No corticosteroid)

LOS in hospital, days:
hydrocortisone group = 23.7 +
36.8,
placebo group = 21.7 + 21.7
(P=0.711)
Shock reversal was similar in
both groups. Hydrocortisone
group = 65.6%, placebo group
= 70.0% (P=0.602)
Early administration of
hydrocortisone enabled earlier
titration off vasoactive therapy.
Norepinephrine duration:
hydrocortisone group = 2.5 +
2.4, placebo group = 2.8 + 4.0
(P=0.639)
The early initiation of lowdose hydrocortisone did not
decrease the risk of mortality
or the length of stay in the ICU
or hospital in adults with septic
shock.
These findings do not support
the use of hydrocortisone in
these patients.

Limitations
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E5: Data Collection Tool 2
Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., … Myburgh, J. (2018). Adjunctive
glucocorticoid therapy in patients with septic shock. The New England Journal of Medicine, 379(9), 797-808.
Identified Placebo Mortality Rate at Day 28

Masked vial
reconstituted to
produce an
equivalent
volume of
placebo (200ml).
(Administration
procedure same
as
hydrocortisone)

Corticosteroid

Placebo
(No corticosteroid)

410 (22.3%)

448 (24.3%)

Key Findings

Limitations

Among patients with septic
shock undergoing mechanical
ventilation, a continuous
infusion of hydrocortisone did
not result in lower 90-day
mortality than placebo
(P=0.50).

The authors did not identify adverse
events themselves. Data on adverse
events were judged by the treating
clinicians thought to be related to the
trial regimen. This judgement was not
adjudicated. This may weaken
inferences about adverse events.

There was no significant
difference in mortality at 28
days (P=0.13).
Hydrocortisone group = 410
(22.3%), placebo group = 448
(24.3%)

Data were not collected regarding all
possible secondary infections. Only
bacteremia and fungemia data was
recorded.

The resolution of shock was
shorter (days) in the
hydrocortisone group
(P<0.001).
Hydrocortisone group = 3,
placebo group = 4
.

The appropriateness of antibiotic
therapy was not adjudicated.
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Identified Placebo Mortality Rate at Day 28
Corticosteroid

Key Findings

Placebo
(No corticosteroid)

Patients receiving
hydrocortisone had a shorter
time to ICU discharge (days)
(P<0.001).
Hydrocortisone group = 10,
placebo group = 12
There was a higher percentage
of adverse events in the
hydrocortisone vs placebo
group (1.1% vs 0.3%,
P=0.009) the most prevalent
being hyperglycemia

Limitations
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E6: Data Collection Tool 2

Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J. P., Siami, S., … Bellissant, E. (2018). Hydrocortisone plus
fludrocortisone for adults with septic shock. New England Journal of Medicine, 378(9), 809-818.
doi: 10.1056/NEJMoa1705716
Identified Placebo Mortality Rate at Day 28
Corticosteroid

Respective
207 (33.7%)
placebos given in
same manner.
Hydrocortisone
placebo =
mannitol
(133.6mg),
disodium
phosphate
(8.73mg), and
sodium phosphate
(0.92mg).
Fludrocortisone
placebo =
microcrystalline
cellulose
(59.098mg),
magnesium
stearate (0.6mg),
and colloidal

Key Findings

Limitations

The relative risk of death was
0.88 (95% CI, 0.78 to 0.99) in
favor of hydro/fludro therapy.
Death occurred in 43% in
hydro/fludro group and 49.1%
in placebo group.

No limitations were reported by the
authors in this study.

Placebo
(No corticosteroid)

244 (38.9%)

Mortality at day 28 was 33.7%
for the hydro/fludro group and
38.9% for the placebo group
(P=0.06).
Mortality was significantly
lower in hydro/fludro group
than placebo group at ICU
discharge (35.4% vs 41%,
P=0.04) and hospital discharge
(39% vs 45.3%, P=0.02).

The trial was suspended twice:
First, from October 2011 to May 2012
after the withdrawal of drotrecogin
alpha from the market.
Second, from July 2014 to October
2014 at the request of the data and
monitoring board to check the quality
of the trial drugs and reported serious
adverse events.
After drotrecogin alpha withdraw, the
trial continued as a two-group parallel
design.
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Identified Placebo Mortality Rate at Day 28
Corticosteroid

anhydrous silica
(0.3mg).

Key Findings

Placebo
(No corticosteroid)

The hydro/fludro group had
more vasopressor-free days (17
+ 11) than placebo group (15 +
11) by day 28 (P<0.001).
The risk of secondary
infection, GI bleeding, or
neurological events was not
significantly higher in the
hydro/fludro group although
the risk of hyperglycemia was
significantly higher in the
hydro/fludro group.

Limitations
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Appendix F1
Study: Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., …
Briegel, J. (2008). Hydrocortisone therapy for patients with septic shock. The England
Journal of Medicine, 358(2), 111-124.
Section A: Are the results of the trial valid?

Yes

1. Did the trial address a clearly focused issue?
2. Was the assignment of patients to treatments
randomised?
3. Were all of the patients who entered the trial properly
accounted for at its conclusion?
One patient withdrew consent after randomization.
4. Were patients, health workers and study personnel
‘blind’ to treatment?
Of note, 4.4% of the hydrocortisone group and 4.0% of the
placebo group received open-label corticosteroids after study
enrollment due to allergic reactions, laryngeal edema,
bronchospasm, brain edema, replacement of long-term
corticosteroid therapy whose history was unknown at
enrollment, acute respiratory distress syndrome, and septic
shock.
5. Were the groups similar at the start of the trial?

ü
ü

6. Aside from the experimental intervention, were the
groups treated equally?
Section B: What are the results?

ü

Can’t
tell

No

ü
ü

ü

7. How large was the treatment effect?
The mortality rate at 28 days was 34.3% (86/251 deaths) in the hydrocortisone group
and 31.5% (78/248 deaths) in the placebo group.
8. How precise was the estimate of the treatment effect?
A sample size of 800 patients was needed to achieve a statistical power of 80% to
detect an absolute decrease in mortality of 10% from an existing death rate of 50% in
patients who did not have a response to corticotropin (40% of total group).
Section C: Will the results help locally?
Yes Can’t
No
tell
ü
9. Can the results be applied to the local population, or in
your context?
ü
10. Were all clinically important outcomes considered?
11. Are the benefits worth the harms and costs?

ü

Critical Appraisal Skills Programme (CASP) Randomised Controlled Trials Checklist
(2018)
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Appendix F2
Study: Arabi Y. M., Aljumah A., Dabbagh O., Tamim H. M., Rishu A. H., AlAbdulkareem, A., … Cherfan A. (2010). Low-dose hydrocortisone in patients with
cirrhosis and septic shock: A randomized controlled trial. Canadian Medical
Association Journal, 182(18), 1971-7. doi: 10.1503/cmaj.090707
Section A: Are the results of the trial valid?
1. Did the trial address a clearly focused issue?
2. Was the assignment of patients to treatments
randomised?
3. Were all of the patients who entered the trial properly
accounted for at its conclusion?
4. Were patients, health workers and study personnel
‘blind’ to treatment?
Of note, blinding was opened for one patient at the request of
the primary physician, but the therapy (placebo) was
continued as planned per the study protocol.
5. Were the groups similar at the start of the trial?
6. Aside from the experimental intervention, were the
groups treated equally?
Five patients in the placebo group were given rescue
corticosteroids for the treatment of life-threatening
hypotension and were considered crossovers.
Section B: What are the results?

Yes

Can’t
tell

No

ü
ü
ü
ü

ü
ü

7. How large was the treatment effect?
The mortality rate at 28 days was 85% (33/39 deaths) in the hydrocortisone group and
72% (26/36 deaths) in the placebo group.
8. How precise was the estimate of the treatment effect?
Based on an estimated baseline 28-day mortality of 90% and an estimated absolute
risk reduction of 20%, 75 patients were required in each group using a two-sided type
I error of 5% and power of 80%.
A planned interim analysis was performed after randomly allocating 75 patients and
found a trend towards excess 28-day mortality with the hydrocortisone group. At this
point the trial was stopped since it was highly unlikely that a significant treatment
benefit would be evident if the trial were completed to the targeted sample size.
Section C: Will the results help locally?
Yes Can’t
No
tell
ü
9. Can the results be applied to the local population, or in
your context?
ü
10. Were all clinically important outcomes considered?
11. Are the benefits worth the harms and costs?

ü
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Appendix F3
Study: Gordon, A. C., Mason, A. J., Perkins, G. D., Stotz, M., Terblanche, M., Ashby,
D., & Brett, S. J. (2014). The interaction of vasopressin and corticosteroids in septic
shock: a pilot randomized controlled trial. Critical Care Medicine 42(6), 1325-1333.
Section A: Are the results of the trial valid?
1. Did the trial address a clearly focused issue?
2. Was the assignment of patients to treatments
randomised?
3. Were all of the patients who entered the trial properly
accounted for at its conclusion?
Two patients met exclusion criteria after randomization, but
before administration of the study drug.
4. Were patients, health workers and study personnel
‘blind’ to treatment?
5. Were the groups similar at the start of the trial?

Yes

Can’t
tell

No

ü
ü
ü

ü
ü
ü

6. Aside from the experimental intervention, were the
groups treated equally?
Due to emergency situations, not all patients received
vasopressin as the initial vasopressor. 30% received
vasopressin as the initial vasopressor and 50% were
transitioned to vasopressin within the first 4 hours of the
onset of shock. Also, eleven patients did not reach maximum
vasopressin requirements so did not receive the study drug.
Section B: What are the results?

7. How large was the treatment effect?
The mortality rate at 28 days was 23% (7/31 deaths) in the hydrocortisone group and
23% (7/30 deaths) in the placebo group.
8. How precise was the estimate of the treatment effect?
30 patients were required in each treatment group in order to study the primary
outcome of the difference in plasma vasopressin concentration between groups.
The group sizes were calculated in order to detect a 33 pmol/L difference in
vasopressin levels at 6-12 hours post corticosteroid administration assuming a SD of
45 pmol/L with a significance level of 0.05 and 80% power.
Section C: Will the results help locally?

Yes

9. Can the results be applied to the local population, or in
your context?
10. Were all clinically important outcomes considered?

ü

11. Are the benefits worth the harms and costs?

ü

ü

Can’t
tell

No
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Appendix F4
Study: Lv, Q., Gu, X., Chen, Q., Yu J., & Zheng, R. (2017). Early initiation of lowdose hydrocortisone treatment for septic shock in adults: A randomized clinical trial.
American Journal of Emergency Medicine, 35(12), 1810-1814.
doi: 10.1016/j.ajem.2017.06.004
Section A: Are the results of the trial valid?
1. Did the trial address a clearly focused issue?

Yes

Can’t
tell

No

ü

2. Was the assignment of patients to treatments
randomised?
3. Were all of the patients who entered the trial properly
accounted for at its conclusion?
4. Were patients, health workers and study personnel
‘blind’ to treatment?
5. Were the groups similar at the start of the trial?
The initial SOFA score was higher in the hydrocortisone
group compared to the placebo group and was statistically
significant (P<0.001).

ü

6. Aside from the experimental intervention, were the
groups treated equally?
Section B: What are the results?

ü

ü
ü
ü

7. How large was the treatment effect?
The mortality rate was 39.7% (23 deaths) in the hydrocortisone group and 31.7% (19
deaths) in the placebo group.
8. How precise was the estimate of the treatment effect?
The study was likely to be underpowered to detect a statistically significant difference
by the recruitment of patients with lower mortality. The original sample size collection
was based on a control mortality of 60% originating from the findings of the largest
prior study, but the control 28-day mortality in this study was almost half that.
Section C: Will the results help locally?

Yes

9. Can the results be applied to the local population, or in
your context?
10. Were all clinically important outcomes considered?

ü

11. Are the benefits worth the harms and costs?

ü

ü

Can’t
tell

No
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Appendix F5
Study: Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., …
Myburgh, J. (2018). Adjunctive glucocorticoid therapy in patients with septic shock.
The New England Journal of Medicine, 379(9), 797-808.
Section A: Are the results of the trial valid?
1. Did the trial address a clearly focused issue?

Yes

Can’t
tell

No

ü

2. Was the assignment of patients to treatments
randomised?
3. Were all of the patients who entered the trial properly
accounted for at its conclusion?
Of the 3800 patients enrolled, 114 patients either withdrew or
did not have informed consent obtained, and 28 patients were
lost to follow-up at 90 days.
4. Were patients, health workers and study personnel
‘blind’ to treatment?
5. Were the groups similar at the start of the trial?

ü

6. Aside from the experimental intervention, were the
groups treated equally?
Section B: What are the results?

ü

ü

ü
ü

7. How large was the treatment effect?
The mortality rate at 28 days was 22.3% (410/1832 deaths) in the hydrocortisone
group and 24.3% (448/1826 deaths) in the placebo group.
8. How precise was the estimate of the treatment effect?
A population of 3800 patients provided the trial with 90% power to detect an absolute
difference of 5% in 90-day all-cause mortality from an estimated baseline mortality of
33%, at an alpha level of 0.05. This allowed for a rate of withdrawal and loss to
follow-up of 1%.
Section C: Will the results help locally?

Yes

9. Can the results be applied to the local population, or in
your context?
10. Were all clinically important outcomes considered?

ü

11. Are the benefits worth the harms and costs?

ü

ü

Can’t
tell

No
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Appendix F6
Study: Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J. P.,
Siami, S., … Bellissant, E. (2018). Hydrocortisone plus fludrocortisone for adults with
septic shock. New England Journal of Medicine, 378(9), 809-818.
doi: 10.1056/NEJMoa1705716
Section A: Are the results of the trial valid?

Yes

1. Did the trial address a clearly focused issue?

ü

2. Was the assignment of patients to treatments
randomised?
3. Were all of the patients who entered the trial properly
accounted for at its conclusion?
4. Were patients, health workers and study personnel
‘blind’ to treatment?
5. Were the groups similar at the start of the trial?

ü

6. Aside from the experimental intervention, were the
groups treated equally?
Section B: What are the results?

Can’t
tell

No

ü
ü
ü
ü

7. How large was the treatment effect?
The mortality rate at 28 days was 33.7% (207/1241 deaths) in the hydrocortisone
group and 38.9% (244/1241 deaths) in the placebo group.
8. How precise was the estimate of the treatment effect?
A 90-day mortality of 45% among patients with septic shock was anticipated. 320
patients were needed in each group to detect an absolute difference of 10% in 90-day
mortality (α=0.05 and power at 95%).
Section C: Will the results help locally?
Yes Can’t
No
tell
ü
9. Can the results be applied to the local population, or in
your context?
ü
10. Were all clinically important outcomes considered?
11. Are the benefits worth the harms and costs?

ü
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Appendix G
Cross Study Analysis
Author, Year
1 Sprung et al.,
2008

2 Arabi et al.,
2010

Mortality Rate at
Day 28

Resolution of Shock

Vasopressor Usage

Corticosteroid: 34.3% Corticosteroid: 79.7% Not reported
Placebo: 31.5
Placebo: 74.2%
P=0.51

P=0.18

Corticosteroid: 85%
Placebo: 72%

Median time to
Reversal (days)
Corticosteroid: 3.3
Placebo: 5.28
Corticosteroid: 62%
Placebo: 39%

P=0.19

P=0.05

Vasopressor-free days
Corticosteroid: 6.8
Placebo: 5.6

Length of Stay (LOS)
ICU
Corticosteroid:
19+31
Placebo:18+17

Hospital
Corticosteroid:
34+41
Placebo: 34+37

P=0.51

P=0.47

Corticosteroid: 9.2
Placebo: 9.6

Corticosteroid:
27.2
Placebo: 43.3

P=0.86
P=0.54

3 Gordon et al.,
2014

Corticosteroid: 23%
Placebo: 23%

Not reported

Days on Vasopressor
Corticosteroid: 2.5+2.4
Placebo: 2.8+4
P=0.001

P=0.90
Not reported

Not reported
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Author, Year

Mortality Rate at
Resolution of Shock
Vasopressor Usage
Day 28
4 Lv et al., 2017 Corticosteroid: 39.7% Corticosteroid: 65.6% Days on Vasopressor
Placebo: 31.7%
Placebo: 70.0%
Corticosteroid: 2.5+2.5
Placebo: 2.8+4.0
P=0.365
P=0.602
P=0.639
5 Venkatesh et
al, 2018

6 Annane et al,
2018

Corticosteroid: 22.3% (Days)
Placebo: 24.3%
Corticosteroid: 3
Placebo: 4
P=0.13
P=<0.001

Not reported

Corticosteroid: 33.7% Not reported
Placebo: 38.9%

Vasopressor-free days
Corticosteroid: 17+11
Placebo: 15+11

Length of Stay (LOS)
ICU
Hospital
Corticosteroid:
Corticosteroid:
10.9+17.5
23.7+36.8
Placebo:
Placebo:
10.2+13.1
21.7+21.7
P=0.799

P=0.711

Corticosteroid: 10
Placebo: 12

Corticosteroid:
39
Placebo: 43

P<0.001
P=0.13

P=0.06
P<0.001

Not reported

Not reported

